Sera Prognostics Company
Sera Prognostics develops blood tests that are predictive of preterm birth, preeclampsia, and other pregnancy complications.
Investors
.png)
Investment Stage:
N/A
Founded Date:
01-01-2008
Investor Type:
Company
Estimated Revenue:
$10M to $50M
Total Funding:
$250,324,197
Investors Number:
13
Employee Number:
51-100
Number Of Exists:
Series D
Last Funding Type:
Series E
Industry:
Pregnancy & Nursing
Technology:
Pregnancy biomarkers
Headquarters:
Salt Lake City, Utah, United States
Funding Status:
IPO
Last Funding Date:
2021-04-28